Preclinical evidence suggested that the IDH1 mutation may contribute to immunosuppressive signaling and that the depletion of CD8+ T cells diminishes the anti-tumor activity of IDH1 inhibitors [90], which raises the possibility of combining IDH1 inhibitors with immunotherapy. This evidence concerns the gene IDH1 and neoplasm.